Kantify

Kantify is a Belgian biotechnology company specializing in AI-driven drug discovery. Their flagship platform, Sapian, utilizes advanced artificial intelligence models to identify small molecules for challenging therapeutic targets, including those previously considered 'undruggable'. Key Offerings Sapian Platform : An AI-powered engine capable of screening vast chemical spaces, analyzing up to 13.6 billion compounds in less than a day. This efficiency allows for the rapid identification of potential drug candidates, significantly accelerating the drug discovery process. (kantify.com ) Therapeutic Focus : Kantify's pipeline includes projects in oncology, neurology, and rare diseases, with notable advancements in soft tissue sarcoma and liposarcoma treatments. (kantify.com ) Values and Unique Aspects Mission-Driven : Founded with the goal of improving human health through AI, Kantify is committed to developing therapies that address unmet medical needs. Innovative Approach : By combining AI with computational biology, Kantify offers a unique solution to the complexities of drug discovery, enabling the identification of effective modulators for any biological target. Collaborative Spirit : The company actively seeks partnerships with pharmaceutical companies and research institutions to further enhance its drug discovery capabilities and bring new treatments to market. Recent Developments Expansion of Screening Capacity : In May 2026, Kantify announced the expansion of Sapian's compound screening capacity to 13.6 billion molecules, maintaining high performance and precision. (kantify.com ) Pipeline Advancements : In December 2025, Kantify reported key scientific advances across its neurology and oncology programs, including positive in vivo antitumor efficacy in soft-tissue sarcoma models. (kantify.com ) Kantify continues to leverage artificial intelligence to revolutionize drug discovery, aiming to deliver breakthrough therapies that change patients' lives.